↓ Skip to main content

Heart Failure

Overview of attention for book
Cover of 'Heart Failure'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 13 Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction
  3. Altmetric Badge
    Chapter 23 Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications
  4. Altmetric Badge
    Chapter 24 Heart Failure Guidelines on Pharmacotherapy
  5. Altmetric Badge
    Chapter 25 Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders
  6. Altmetric Badge
    Chapter 27 Comorbidities in Heart Failure
  7. Altmetric Badge
    Chapter 28 Vasopressin and Vasopressin Antagonists in Heart Failure
  8. Altmetric Badge
    Chapter 30 Iron Deficiency Treatment in Patients with Heart Failure
  9. Altmetric Badge
    Chapter 31 Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction
  10. Altmetric Badge
    Chapter 55 Ivabradine.
  11. Altmetric Badge
    Chapter 56 Wnt Signaling in Cardiac Remodeling and Heart Failure
  12. Altmetric Badge
    Chapter 74 Epidemiology of Heart Failure
  13. Altmetric Badge
    Chapter 75 Clinical Trial Design, Endpoints, and Regulatory Requirements
  14. Altmetric Badge
    Chapter 76 Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
  15. Altmetric Badge
    Chapter 77 Sacubitril/Valsartan (LCZ696) in Heart Failure
  16. Altmetric Badge
    Chapter 80 Platelet-Derived Growth Factor in Heart Failure
  17. Altmetric Badge
    Chapter 81 Gene Therapy in Heart Failure
  18. Altmetric Badge
    Chapter 82 Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease
  19. Altmetric Badge
    Chapter 83 Partial Adenosine A1 Agonist in Heart Failure
  20. Altmetric Badge
    Chapter 86 Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction
  21. Altmetric Badge
    Chapter 88 New and Emerging Therapies and Targets: Beta-3 Agonists
  22. Altmetric Badge
    Chapter 99 Noncoding RNAs in Heart Failure
  23. Altmetric Badge
    Chapter 100 Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure
  24. Altmetric Badge
    Chapter 101 The Three-Decade Long Journey in Heart Failure Drug Development
  25. Altmetric Badge
    Chapter 123 Mitochondrial Therapies in Heart Failure
  26. Altmetric Badge
    Chapter 126 Anticoagulation Therapy and NOACs in Heart Failure
Attention for Chapter 76: Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
1 news outlet
twitter
1 X user
wikipedia
1 Wikipedia page

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
89 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
Chapter number 76
Book title
Heart Failure
Published in
Handbook of experimental pharmacology, January 2016
DOI 10.1007/164_2016_76
Pubmed ID
Book ISBNs
978-3-31-959658-7, 978-3-31-959659-4
Authors

Peter Kolkhof, Frederic Jaisser, So-Young Kim, Gerasimos Filippatos, Christina Nowack, Bertram Pitt, Kolkhof, Peter, Jaisser, Frederic, Kim, So-Young, Filippatos, Gerasimos, Nowack, Christina, Pitt, Bertram

Abstract

Characterization of mice with cell-specific deletion or overexpression of the mineralocorticoid receptor (MR) shed a new light on its role in health and disease. Pathophysiological MR activation contributes to a plethora of deleterious molecular mechanisms in the development of cardiorenal diseases like chronic kidney disease (CKD) and heart failure (HF). Accordingly, the available steroidal MR antagonists (MRAs) spironolactone (first generation MRA) and eplerenone (second generation MRA) have been shown to be effective in reducing cardiovascular (CV) mortality and morbidity in patients with chronic HF and a reduced left ventricular ejection fraction (HFrEF). However, they remain underutilized, in large part owing to the risk inducing severe adverse events including hyperkalemia and worsening of kidney function, particularly when given on top of inhibitors of the renin angiotensin system (RAS) to patients with concomitant kidney dysfunction. Novel, potent, and selective non-steroidal MRAs (third generation) were identified in drug discovery campaigns and a few entered clinical development recently. One of these is finerenone with different physicochemical, pharmacokinetics, and pharmacological properties in comparison with the steroidal MRAs. Available data from five clinical phase II trials with finerenone in more than 2,000 patients with HF and additional CKD and/or diabetes as well as in patients with diabetic kidney disease demonstrated that neither hyperkalemia nor reductions in kidney function were limiting factors to its use. Moreover, finerenone demonstrated a nominally improved outcome compared to eplerenone in a phase IIb trial with 1,066 patients with HFrEF and concomitant type 2 diabetes mellitus (T2DM) and/or CKD.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 89 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 12%
Student > Bachelor 11 12%
Researcher 9 10%
Student > Doctoral Student 7 8%
Student > Postgraduate 6 7%
Other 16 18%
Unknown 29 33%
Readers by discipline Count As %
Medicine and Dentistry 26 29%
Biochemistry, Genetics and Molecular Biology 14 16%
Agricultural and Biological Sciences 5 6%
Chemistry 3 3%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 6 7%
Unknown 33 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2020.
All research outputs
#2,489,325
of 23,327,904 outputs
Outputs from Handbook of experimental pharmacology
#87
of 650 outputs
Outputs of similar age
#44,569
of 396,138 outputs
Outputs of similar age from Handbook of experimental pharmacology
#6
of 55 outputs
Altmetric has tracked 23,327,904 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 650 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 396,138 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.